Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 30Carcinoma, Hepatocellular 22Small Cell Lung Carcinoma 15Colorectal Neoplasms 14Carcinoma, Non-Small-Cell Lung 14Sarcoma 13Ovarian Neoplasms 12Breast Neoplasms 12Triple Negative Breast Neoplasms 9Nasopharyngeal Carcinoma 9Esophageal Squamous Cell Carcinoma 9Cholangiocarcinoma 9Biliary Tract Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Osteosarcoma 6Lung Neoplasms 6Pancreatic Neoplasms 5Head and Neck Neoplasms 5Esophageal Neoplasms 5Uterine Cervical Neoplasms 4Thyroid Neoplasms 4Neoplasms 4Melanoma 4Solid Tumor 3Recurrence 3Neoplasm Metastasis 3Liver Neoplasms 3Glioma 3Gastric Adenocarcinoma 3Carcinoma, Adenoid Cystic 3

Interventions

irinotecan sucrosofate 1apatinib 1Temozolomide 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Efficacy and Safety × apatinib × Clear all
NCT03660761 2019-04-16

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Shandong Cancer Hospital and Institute

Phase 2 Completed
25 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡